

ASX ANNOUNCEMENT

ASX:RSH OTCQB:RSHUF



7 December 2022

RESPIRI SECURES FIRST PRIMARY CARE SPECIALTY PRACTICE IN GEORGIA, USA, WITH FIRST PATIENTS COMMENCED ON wheezo® REMOTE PATIENT MONITORING PROGRAM

Highlights:

- wheezo® and Access Telehealth Remote Patient Monitoring (RPM) program selected by a primary care practice in Georgia, USA, to improve the management of patients suffering from asthma. The practice provides ongoing healthcare services to thousands of patients.
- First patients have commenced on the wheezo® RPM program.
- RPM Current Procedural Terminology (CPT) reimbursement claims to be processed within the next 2 months.
- RPM solutions delivered through Access Telehealth will include the full-service premium model that includes patient engagement using their cloud-based platform, Remotli.

Respiri Limited (ASX:RSH, OTCQB:RSHUF) ("Respiri" or the "Company"), an eHealth SaaS Company supporting respiratory health management is pleased to announce it has secured its first Primary Care Practice, Medical Center of Conyers, located just outside Atlanta, Georgia and patients with respiratory disorders have commenced on the wheezo® RPM program.

Respiri's remote patient monitoring (RPM) partner Access Telehealth will provide a full RPM solution that includes the Remotli platform, patient engagement and remote monitoring to these patients under the supervision of family care physicians. The clinic is a long-established practice that provides ongoing healthcare to thousands of patients.

RPM (CPT) reimbursement codes from this program are to be processed through Centers for Medicare and Medicaid Services (CMS) and private insurers providing remuneration to the practice for delivering this new patient service. Respiri will generate revenues from device sales (USD\$50-USD\$60 per device) and a monthly fee per patient per month of between USD\$10-USD\$20 depending on the breadth of services provided by its partner Access Telehealth.

Respiri has now secured healthcare organisation customers located in five different states in the USA that treat and manage pediatric patients with asthma, elderly patients with COPD, patients specifically with respiratory complications, cardiovascular disease patients with COPD comorbidities and primary care patients demonstrating the broad clinical setting appeal of the wheezo® RPM program.

Marjan Mikel, CEO of Respiri said, "Although respiratory specialists remain our key targets for wheezo® RPM, the fact remains that family medical practitioners are heavily involved in the management of patients with asthma and COPD. Having wheezo® RPM prescribed by this group for the management of respiratory disorders should help improve patient well-being and reduce disease complications and further broaden our program patient reach."

"I was also present as three patients commenced on wheezo® and the relief they expressed knowing that they now have an "early warning system" connected to their physician presented first-hand experience of why our business

ASX ANNOUNCEMENT

ASX:RSH OTCQB:RSHUF

is so important. It was very satisfying.”

Respiri together with RPM partners are in advanced discussions with a number of other potential wheezo® RPM healthcare organisation customers who also see the benefits of introducing wheezo® RPM services as part of their patient standard of care.



Figure 1. First patients enrolled in the wheezo® RPM program in Georgia, USA with Marjan Mikel second from the left (Respiri CEO) and Lisa Dye, far right (Chief Commercial Officer Access Telehealth)

This announcement was approved for release by the Board of Respiri Limited.

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respiri Limited
P: +61 408 462 873
E: marjan@respiri.co

Mr Nicholas Smedley
Executive Chairman
Respiri Limited
P: +61 447 074 160
E: nicholas@respiri.co

wheezo® is a registered trademark of Respiri Limited.

ASX ANNOUNCEMENT

ASX:RSH OTCQB:RSHUF

About Respi Limited

Respi Limited (ASX:RSH, OTCQB:RSHUF) is an international e-Health SaaS company supporting respiratory health management focusing primarily on supporting the US remote patient monitoring market. Its world-first technology detects wheeze, a typical symptom of Asthma, COPD and respiratory disease to provide an objective measure of airway limitation. Respi created technology optimises how patients in partnership with their physicians manage chronic respiratory conditions. These solutions can help transform the way physicians interact with respiratory patients while they are away from the clinic. wheezo®, is an FDA cleared Class II Medical Device, the respi™ app (patient-user-interface) and the secure health portal can help different health organisations and providers connect with patients to improve collaboration and help improve respiratory condition management. In the USA, wheezo® can be integrated into Remote Patient Monitoring (RPM) programs and qualifies for RPM Current Procedural Terminology (CPT) reimbursement.

Respi's mission is to help improve quality of life for hundreds of millions of children and adults around the world with respiratory disorders and dramatically reduce hospital admissions and the economic burden of Asthma and COPD. Respi Limited's operations are based in Melbourne, Australia with offices in New York City, USA.

For additional information about Respi Limited please visit our corporate website www.respi.co/au

About wheezo®

Developed in Australia, with the support of an international panel leading respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the intuitive mobile application engages patients to log symptoms and triggers to build a personal profile to share data with healthcare providers so patients and physicians can have more informed discussions in relation to symptoms. The platform has been designed to extend care beyond the clinic which may lead to better health outcomes and improved quality of life for patients.

For information about our product offering in the US including wheezo® please visit www.respi.co/us

wheezo® is a registered trademark of Respi Limited.

About Access Telehealth

Access Telehealth is a digital health company dedicated to delivering innovative connected care solutions for management of people living with chronic disease. The Remotli platform uniquely simplifies remote care delivery with patient engagement and productivity driven dashboard tools to support effective patient care and compliance. Automated care-time tracking, and reimbursement reports makes it easy to boost revenue to support vital chronic disease management programs including Remote Physiologic Monitoring, Remote Therapeutic Monitoring, Transitional Care, Chronic Care Management, Telemedicine and more. Focusing on Remote Physiologic Monitoring and virtual care initiatives, the Access Telehealth clinical team delivers patient-centric remote monitoring services to support disease specific chronic care programs for health systems, payors, and providers, to enhance care delivery. www.accessrpm.com/

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but are based on Respi current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respi, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respi cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respi only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respi will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.